ABBV ready for shortABBV seems ready for short, RSI already broken trend line.
Details are on chart.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.78 EUR
4.09 B EUR
54.42 B EUR
1.76 B
About AbbVie Inc.
Sector
Industry
CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
ISIN
US00287Y1091
FIGI
BBG003Q17NS4
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where 4AB is featured.
Frequently Asked Questions
The current price of 4AB is 187.00 EUR — it has decreased by −0.65% in the past 24 hours. Watch AbbVie, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange AbbVie, Inc. stocks are traded under the ticker 4AB.
4AB stock has risen by 2.12% compared to the previous week, the month change is a 3.74% rise, over the last year AbbVie, Inc. has showed a 6.83% increase.
We've gathered analysts' opinions on AbbVie, Inc. future price: according to them, 4AB price has a max estimate of 229.53 EUR and a min estimate of 165.77 EUR. Watch 4AB chart and read a more detailed AbbVie, Inc. stock forecast: see what analysts think of AbbVie, Inc. and suggest that you do with its stocks.
4AB stock is 1.50% volatile and has beta coefficient of 0.38. Track AbbVie, Inc. stock price on the chart and check out the list of the most volatile stocks — is AbbVie, Inc. there?
Today AbbVie, Inc. has the market capitalization of 323.33 B, it has increased by 0.78% over the last week.
Yes, you can track AbbVie, Inc. financials in yearly and quarterly reports right on TradingView.
AbbVie, Inc. is going to release the next earnings report on Oct 24, 2025. Keep track of upcoming events with our Earnings Calendar.
4AB earnings for the last quarter are 2.52 EUR per share, whereas the estimation was 2.44 EUR resulting in a 3.12% surprise. The estimated earnings for the next quarter are 2.76 EUR per share. See more details about AbbVie, Inc. earnings.
AbbVie, Inc. revenue for the last quarter amounts to 13.09 B EUR, despite the estimated figure of 12.76 B EUR. In the next quarter, revenue is expected to reach 13.17 B EUR.
4AB net income for the last quarter is 787.78 M EUR, while the quarter before that showed 1.18 B EUR of net income which accounts for −33.21% change. Track more AbbVie, Inc. financial stats to get the full picture.
Yes, 4AB dividends are paid quarterly. The last dividend per share was 1.41 EUR. As of today, Dividend Yield (TTM)% is 2.99%. Tracking AbbVie, Inc. dividends might help you take more informed decisions.
AbbVie, Inc. dividend yield was 3.54% in 2024, and payout ratio reached 263.15%. The year before the numbers were 3.87% and 220.33% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 18, 2025, the company has 55 K employees. See our rating of the largest employees — is AbbVie, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbbVie, Inc. EBITDA is 22.71 B EUR, and current EBITDA margin is 44.40%. See more stats in AbbVie, Inc. financial statements.
Like other stocks, 4AB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbbVie, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbbVie, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbbVie, Inc. stock shows the strong buy signal. See more of AbbVie, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.